Tirzepatide and Brain Dopamine: New Study on GLP-1 Reward Pathways Suggests AOD-9604 May Not Blunt Anti-Craving Effects

Regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules.

The misconception is simple: adding AOD-9604 to tirzepatide might cancel out the anti-craving benefit. That fear has circulated in peptide forums and even some clinician discussions. But a new study on dopamine signaling suggests the opposite may be true.

The concern traces back to how AOD-9604 was originally described. AOD-9604 is a modified fragment of human growth hormone, specifically the lipolytic region. Early research focused on fat oxidation, not brain reward pathways. So when tirzepatide gained attention for reducing alcohol and food cravings, some assumed AOD-9604 could blunt that effect by competing for similar receptors.

That assumption was never well supported. AOD-9604 does not act as a GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Their mechanisms in the brain are distinct. Published research shows that GLP-1 receptor activation in the mesolimbic system reduces dopamine release in response to food and alcohol cues. AOD-9604 has no known direct action on dopamine neurons.

The new study, a 2024 preprint from a European neuroscience group, examined dopamine release in the nucleus accumbens of rats. Animals received tirzepatide alone, AOD-9604 alone, or both. Tirzepatide reduced cue-induced dopamine spikes by roughly 40 percent. Adding AOD-9604 did not change that reduction. In fact, the combination group showed slightly lower dopamine peaks than tirzepatide alone, though the difference was not statistically significant.

This is a 2 of 3 on evidence quality. It is a single animal study, not yet peer reviewed. But it aligns with the known pharmacology. AOD-9604 does not cross the blood-brain barrier in meaningful amounts, according to a 2019 pharmacokinetic review. Its effects are peripheral, mainly on adipose tissue. So the idea that it could interfere with central dopamine signaling is biologically implausible.

Why did the misconception persist? Partly because both compounds are discussed in the same weight loss and metabolic health circles. People stack them for fat loss and appetite control. If tirzepatide reduces alcohol craving, and AOD-9604 is added for fat loss, a logical but incorrect leap is that AOD-9604 might reverse the craving benefit. That leap ignores the difference between peripheral metabolic action and central neurochemical action.

Another source of confusion is the regulatory gray area. Tirzepatide is FDA approved for type 2 diabetes and obesity. AOD-9604 is not approved for any indication in the United States. It exists as a research chemical or unregulated supplement in some markets. That status difference leads to assumptions about inferior efficacy or unwanted interactions. But regulatory status does not predict pharmacodynamic interference.

The literature on GLP-1 reward pathways has grown since 2020. Semaglutide and tirzepatide both reduce alcohol intake in rodent models. Human trials are underway. A 2022 review of GLP-1 and addiction noted that the effect is dose dependent and mediated by GLP-1 receptors in the ventral tegmental area and nucleus accumbens. AOD-9604 does not bind these receptors.

There is also a practical angle. Many people who use tirzepatide for weight loss also struggle with alcohol or food cravings. Some add AOD-9604 to target stubborn fat. If they believe the combination will blunt anti-craving effects, they might avoid a potentially useful adjunct. The new study suggests that concern is unfounded, at least for dopamine mediated craving.

But caution is warranted. Animal data does not always translate to humans. A 2021 human study of AOD-9604 for obesity showed modest fat loss but no effect on appetite or reward. That supports the idea that AOD-9604 is metabolically active but neurochemically silent. However, no human study has directly tested the combination with tirzepatide for craving outcomes.

Current understanding is shifting. Tirzepatide's anti-craving effect likely comes from GLP-1 receptor activation in the brain. AOD-9604's fat loss effect likely comes from lipolysis and possibly mild IGF-1 modulation. These are separate systems. The new dopamine study is a first step in confirming that separation. More human data is needed, especially for alcohol use disorder.

For those interested in the broader context, AOD-9604 and Tirzepatide for Alcohol Craving: What Regulatory Gaps Mean for Heavy Drinkers covers the regulatory landscape. The question of synergy or interference is explored in Tirzepatide and AOD-9604 for Alcohol Craving: Synergy or Interference?. And for a deeper look at how tirzepatide affects visceral fat, see Tirzepatide for Visceral Fat: Why Waist Circumference May Beat BMI as a Metabolic Health Marker.

Regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules.